Integra LifeSciences Holdings Corporation (IART): Price and Financial Metrics

Integra LifeSciences Holdings Corporation (IART)

Today's Latest Price: $69.64 USD

0.34 (0.49%)

Updated Jan 25 9:44am

Add IART to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 186 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

IART Stock Summary

  • With a one year PEG ratio of 323.05, Integra Lifesciences Holdings Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 88.65% of US stocks.
  • With a price/earnings ratio of 103.42, Integra Lifesciences Holdings Corp P/E ratio is greater than that of about 90.29% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for Integra Lifesciences Holdings Corp is higher than 81.74% of stocks in our set with a positive cash flow.
  • If you're looking for stocks that are quantitatively similar to Integra Lifesciences Holdings Corp, a group of peers worth examining would be CMD, CW, CMCO, HRC, and EPC.
  • IART's SEC filings can be seen here. And to visit Integra Lifesciences Holdings Corp's official web site, go to

IART Stock Price Chart Interactive Chart >

Price chart for IART

IART Price/Volume Stats

Current price $69.64 52-week high $70.67
Prev. close $69.30 52-week low $34.21
Day low $68.76 Volume 5,875
Day high $69.64 Avg. volume 356,988
50-day MA $60.95 Dividend yield N/A
200-day MA $51.62 Market Cap 5.87B

Integra LifeSciences Holdings Corporation (IART) Company Bio

Integra LifeSciences develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neuro-surgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International. The company was founded in 1989 and is based in Plainsboro, New Jersey.

IART Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$69.64$36.03 -48%

We started the process of determining a valid price forecast for Integra Lifesciences Holdings Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Integra Lifesciences Holdings Corp ranked in the 36th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Integra Lifesciences Holdings Corp ended up being:

  • The company's compound free cash flow growth rate over the past 5.5 years comes in at 0.19%; that's greater than 55.66% of US stocks we're applying DCF forecasting to.
  • Integra Lifesciences Holdings Corp's effective tax rate, as measured by taxes paid relative to net income, is at 14 -- greater than 54.18% of US stocks with positive free cash flow.
  • The weighted average cost of capital for the company is 8. This value is greater than merely 20.49% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as IART, try PKI, MMSI, CRL, TMO, and A.

IART Latest News Stream

Event/Time News Detail
Loading, please wait...

IART Latest Social Stream

Loading social stream, please wait...

View Full IART Social Stream

Latest IART News From Around the Web

Below are the latest news stories about Integra Lifesciences Holdings Corp that investors may wish to consider to help them evaluate IART as an investment opportunity.

Integra (IART) Acquires Acell, Focuses on Regenerative Space

The acquisition is expected to remain accretive to Integra's (IART) revenue growth and adjusted gross margins.

Yahoo | January 21, 2021

Integra LifeSciences Completes the Acquisition of ACell, Inc.

PRINCETON, N.J., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it completed the previously-disclosed acquisition of ACell, Inc. “Acquiring ACell and its proprietary MatriStem UBM™ technologies will enable Integra to provide more comprehensive complex wound management solutions to address our customers’ most pressing clinical challenges,” said Peter Arduini, president and CEO, Integra LifeSciences. “Together with ACell colleagues, we look forward to continuing to advance wound care innovations for our customers and patients.” Sullivan & Cromwell LLP is acting as legal advisor to Integra. About Integra LifeSciencesIntegra LifeSciences is a global leader in regenerative tissue technolo...

Yahoo | January 20, 2021

BTIG Stick to Their Buy Rating for Integra Lifesciences Holdings Corp. By

BTIG Stick to Their Buy Rating for Integra Lifesciences Holdings Corp. | January 19, 2021

Integra (IART) Sells Unprofitable Arm to Focus on Core Business

Integra (IART) does not expect the selloff to have a material impact on its 2020 results.

Yahoo | January 5, 2021

Integra LifeSciences Completes the Sale of its Extremity Orthopedics Business to Smith+Nephew

PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has completed its previously announced divestiture of its Extremity Orthopedics business to Smith+Nephew (LSE:SN, NYSE:SNN). “With this divestiture, we will now be in an even stronger position to capitalize on our core products and technologies in neurosurgery and regenerative medicine, and provide greater value to our customers and shareholders,” said Peter Arduini, president and CEO, Integra LifeSciences. “We want to thank the orthopedics team for their contributions to Integra’s success and wish them all the best for their future.”Piper Sandler & Co. is serving as financial advisor and Morgan, Lewis & Bockius LLP...

Yahoo | January 4, 2021

Read More 'IART' Stories Here

IART Price Returns

1-mo N/A
3-mo 49.60%
6-mo 40.04%
1-year 26.14%
3-year 30.95%
5-year 124.25%
YTD 7.27%
2020 11.39%
2019 29.22%
2018 -5.77%
2017 11.57%
2016 26.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9917 seconds.